Arch holding strong ahead of trial data. Long

ARCH BIOPARTNERS INCTSXV

Description

⋅ Feb 11, 2022 12:04 AM

With Trial data coming up the company is set for a bull run but in the meantime it has enough buyer interest to hold with strong support.

⋅ Mar 2, 2022 12:16 AM

Dragged down by bad macro. Still a good stock but the market conditions are just not ideal.